CLRB

Cellectar Biosciences INC NEW

$2.97 -5.41%

Recent alerts on CLRB

All signals →

News Cellectar plans Phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027

SEC filing CLRB Reports Q1 2026 Net Loss $5.7M, $1.33 Loss per Share

Insider trade Purchase by James V Caruso (Chief Executive Officer)

Insider trade Purchase by Jarrod Longcor (Chief Operating Officer)

News Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News

News Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News

Get push alerts for CLRB

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS